The George Institute
87
19
20
49
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.0%
7 terminated/withdrawn out of 87 trials
87.5%
+1.0% vs industry average
43%
37 trials in Phase 3/4
8%
4 of 49 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (87)
HFrEF Polypill in Sri Lanka RCT
Role: collaborator
Working Out M0 Bipolar Androgen Therapy
Role: collaborator
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Role: lead
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
Role: lead
Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
Role: lead
The RAFT ECT Study
Role: lead
Cognitive Level Enhancement Through Vision Exams and Refraction
Role: collaborator
PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury
Role: lead
Effects of Advanced Trauma Life Support® on Adult Trauma Patient Outcomes
Role: collaborator
FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
Role: lead
Global Kidney Patient Trials Network
Role: lead
INTERACT4 Expansion - Validation Study
Role: lead
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
Role: collaborator
Prevention of Serious Adverse Events Following Angiography
Role: collaborator
Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis
Role: lead
SMART Health Pregnancy 2 - Intervention to Reduce Anaemia and Cardiometabolic Risk During Pregnancy and in the First Year Following Birth
Role: lead
Trial of Enhanced Neurostimulation for Anorexia
Role: lead
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial
Role: lead
Optimised Treatment for Hypertension Trial
Role: lead
Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression
Role: lead